Is radioiodine administration in patients with papillary thyroid multifocal microcarcinoma unnecessary?

Eva Krčálová1,5, Jiří Horáček2,5, Lubomír Kudlej3, Viera Rousková4, Blanka Michlová1, Irena Vyhánková1, Jiří Doležal1, Jaroslav Malý2,5 and Pavel Žák2,5

1Nuclear Medicine Department, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, 24th Department of Internal Medicine, Charles University in Prague, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic, 3Internal Medicine Department, 4Nuclear Medicine Department, Hospital Trutnov, Trutnov, Czech Republic, and 5Academic Department of Internal Medicine, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic

Summary

Radioiodine (RAI) has played a crucial role in differentiated thyroid cancer treatment for more than 60 years. However, the use of RAI administration in patients with papillary thyroid microcarcinoma (even multifocal) is now being widely discussed and often not recommended. In accordance with European consensus, and contrary to the American Thyroid Association (ATA) guidelines, we recently performed RAI thyroid remnant ablation in a patient with differentiated papillary multifocal microcarcinoma. The post-therapeutic whole-body scan and SPECT/CT revealed the real and unexpected extent of disease, with metastases to upper mediastinal lymph nodes. This finding led to the patient’s upstaging from stage I to stage IVa according to the American Joint Committee on Cancer/International Union Against Cancer criteria.

Learning points:

1. ¹³¹I is a combined beta–gamma emitter, thus allowing not only residual thyroid tissue ablation but also metastatic tissue imaging.
2. RAI remnant ablation omission also means post-treatment whole-body scan omission, which may lead to disease underestimation, due to incorrect nodal and metastatic staging.
3. RAI should be considered also in “low-risk” patients, especially when the lymph node involvement is not reliably documented.
4. Lower administered RAI activity (30 mCi, 1.1 GBq) may be a workable compromise in low-risk patients, not indicated for RAI remnant ablation according to ATA guidelines.

Background

Differentiated thyroid cancer (DTC) therapy has long consisted of total thyroidectomy, occasionally accompanied by neck lymph node dissection, radioiodine (RAI) administration and levothyroxine suppression therapy. Due to a sharp increase in the incidence of DTC, with prevailing small (below 2 cm), low-risk tumours (1), the necessity of RAI remnant ablation in these low-risk patients has recently been discussed (2, 3).
American Thyroid Association (ATA) guidelines do not recommend RAI remnant ablation in patients with well-differentiated microcarcinoma, even multifocal, in the absence of worrisome histological features (4).

According to European consensus, RAI administration is probably indicated even in patients with microcarcinoma if no neck lymph node dissection was performed (5).

While retrospective studies suggest that RAI omission does not influence long-term outcome in low-risk patients (4, 5, 6), there are no reliable data from long-term prospective randomised controlled studies, which leaves this question open (7).

In addition, RAI treatment also provides an important diagnostic tool in accurate TNM disease staging, as demonstrated in our case report.

Case presentation

In a 62-year-old man, laboratory tests on routine screening revealed hyperthyroidism: thyrotrophin (TSH) 0.065 mIU/L, free thyroxine (fT4) 16.67 pmol/L, and free triiodothyronine (fT3) 9.61 pmol/L. Methimazole (30 mg/day) was administered and the patient was referred to an endocrinologist.

Investigation

The endocrinologist checked the laboratory tests: TSH, fT4, and fT3 were then normalised due to the methimazole treatment. Thyroid gland ultrasonography disclosed a hypoechoic inhomogeneous nodule (20 mm) with calcifications in the lower part of the right lobe. In addition, several small cysts (up to 5 mm) in the upper part of the right lobe were described. The appearance of the left lobe was unremarkable and lymphadenopathy was not present. Static thyroid gland scintigraphy with \(^{99m}\)Tc-pertechnetate confirmed a small warm nodule in the lower part of right thyroid lobe, corresponding to the nodule on ultrasonography (Fig. 1).

Right thyroid lobe resection was performed, and histology revealed not only the hyperplastic nodule but also 3 foci of papillary microcarcinoma – all within 6 mm. One of them was a follicular variant of papillocarcinoma. The presence of locoregional or vascular invasion was not detected. Completion thyroidectomy was performed within 10 days. In the left lobe, no cancer was found. As no enlarged lymph nodes were detected preoperatively, no lymph node dissection was performed.

Treatment

After 6 weeks of thyroid hormone withdrawal, the patient was admitted to our thyroid unit for RAI remnant ablation. He was hypothyroid as required (TSH level above 50 mIU/L, undetectable fT4, and low fT3). Ultrasonography showed only small remnants in the thyroid bed and no suspicious neck lymph nodes. RAI uptake after 24 h was only 2.3%, thus meeting the RAI remnant ablation requirements. Serum thyroglobulin (Tg) level was 11.03 μg/mL. The patient underwent RAI remnant ablation with 100 mCi (3.7 GBq) \(^{131}\)I.

Outcome and follow-up

The post-ablation scan revealed not only remnants in the thyroid bed, but surprisingly also metastatic lymphatic tissue in the upper mediastinum (two lymph nodes in front of the trachea and one in front of the upper vena cava – as clearly visible on the SPECT/CT) (Figs 2 and 3).

This changed his TNM classification from T1a(m) N0M0 to T1a(m)N1bM0, and the staging from stage I to stage IVa, according to American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) criteria.
Discussion

ATA does not recommend RAI ablation for patients with microcarcinomas or multifocal cancer when the foci are smaller than 1 cm (4). This approach seems to be supported by several studies. For example, Schwartz et al. in their retrospective cohort study with 1298 patients (and a follow-up period of 10 years) did not show any survival benefit of RAI ablation in low-risk patients (defined according to ATA guidelines) (6).

Nevertheless, who are the low-risk patients?

Our case report highlights the sticking point of thyroid cancer management, i.e. reliable lymph node evaluation. Moreover, this is the crucial point because, in the presence of lymph node metastases, the patient is certainly not low-risk according to any recommendation (4, 5). Still, at the time of decision for or against RAI remnant ablation, the ‘negative’ information on metastatic lymph nodes may not be very reliable.

ATA guidelines do not recommend lymph node dissection in T1 and T2 tumours. European consensus advises neck lymph node dissection only if there is a suspicion. Therefore, for most patients, we do not have any direct data from surgery and histology. According to European consensus, such patients would be in the ‘probable indication’ group for RAI administration (5), as it was in our patient.

Ultrasonography may be a workable alternative, but it is highly operator-dependent, and often not sufficiently sensitive. Using post-ablation SPECT/CT in 85 patients with microcarcinoma and no suspected nodal involvement at ultrasonography, Gallicchio et al. found 30 (i.e. 35%) metastatic neck lymph nodes (8). Furthermore, mediastinal lymph nodes are sonographically unattainable at all (unless very proximal). Our case report demonstrates this problem clearly.

Therefore, the real extent of the disease after surgery may not be well documented. As also small ‘low-risk’ tumours below 10 mm may produce nodal or distant metastases, some authors still advocate RAI remnant ablation in all DTC patients (2, 7), in contrast to the official recommendations (4, 5). In fact, while heterogeneous population of low-risk DTC patients is rapidly growing,
we have not had any data from sufficiently long-term prospective randomised studies comparing the relapse rate and survival in low-risk DTC patients supporting either liberal or strict approach towards radioiodine remnant ablation.

Certainly, survival in DTC is greatly affected by careful lifelong follow-up, as many patients with relapsing disease can be successfully treated with RAI. Another argument for a more liberal approach towards RAI treatment in low-risk patients may be that post-surgical RAI remnant ablation makes this follow-up (using thyroglobulin levels and RAI scintigraphy) more efficient.

From carefully designed randomised controlled studies by Schlumberger et al. (9) and Malick et al. (10), we know that remnant ablation may be successfully performed using a lower activity (30 mCi, 1.1 GBq), with lower radiation exposure. While we do not know how the lower activity will affect the long-term relapse rate and survival, it may also be useful in lymph node involvement detection, thus making the staging more precise.

Using lower activity may thus be a workable theranostic alternative in ‘low-risk’ DTC patients with unreliable information on the lymph node involvement.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by grant SVV-2016-260286.

Patient consent
The patient’s informed consent for the article and accompanying image publication was obtained. A signed copy of informed consent is enclosed.

Author contribution statement
E Krčállová wrote the manuscript and prepared the volume-rendering technique reconstructions. B Michlová is the patient’s physician; B Michlová gave E Krčállová permission to write the manuscript. L Kudlej is the endocrinologist. V Rousková, B Michlová, and I Vyhňáková performed the nuclear medicine imaging studies. J Horáček, J Doležal, J Malý, and P Žák gave important clinical advice, reviewed the manuscript, and contributed to the discussion.

References
3 Lamartina L & Cooper DS 2015 Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: the “con” point of view. Endocrine 50 67–71. (doi:10.1007/s12020-014-0523-4)